Software as a Medical Device market seen hitting $80.12 billion by 2035

Market Research Future projects the global Software as a Medical Device market will rise from $5.56 billion in 2026 to $80.12 billion by 2035, driven by faster FDA update pathways, new reimbursement codes and cloud-edge AI adoption. The outlook points to broader commercialization as regulators and payers make standalone medical software easier to deploy and bill for.

Why it matters: - Software as a Medical Device is moving from niche clinical tool to mainstream healthcare infrastructure. - The market's growth is tied to reimbursement and regulation, not just hospital spending. - Faster approvals and new billing pathways could make AI-driven diagnostics and monitoring more financially viable for health systems.

What happened: - Market Research Future projected the global Software as a Medical Device market will reach $80.12 billion by 2035, up from $5.56 billion in 2026. - The forecast implies a 34.5% compound annual growth rate from 2026 to 2035. - The market base was estimated at $4.08 billion in 2025. - The report framed the expansion around FDA change-control rules, payer reimbursement code growth and cloud-native AI adoption. - Market Research Future offered a free sample report at Request a Free Sample.

The details: - The FDA's 2023 guidance allows manufacturers to set an algorithm change protocol at initial approval, reducing the need for a new 510(k) submission after every retraining cycle. - By early 2025, more than 40 authorized marketing applications referenced that approach, and average time-to-update fell from 14 months to less than 90 days. - CMS activated three new Category I CPT codes in January 2025 for autonomous AI diagnostic interpretations covering diabetic retinopathy screening, cardiac ejection-fraction estimation and stroke-triage notification. - Germany's DiGA framework already reimburses several mental-health applications, and France, Belgium and the Czech Republic are adapting similar models. - The UK's NICE evidence standards for digital health and France's PECAN early-access scheme are also widening reimbursement pathways. - Health-cloud sales on AWS, Azure and GCP crossed $18 billion in 2024. - Qualcomm and Apple have introduced edge inference chips that support local model execution on smartphones and wearables. - Global smartwatch and health-tracker shipments exceeded 230 million units in 2024. - Products with native FHIR-based EHR integrations see roughly 2.5 times faster enterprise rollout. - Cloud-based deployment held a 68.2% revenue share in 2025. - Screening and early detection led applications with a 42.1% revenue share in 2025. - Hospitals and clinics remained the largest end-user segment at 43.9% share in 2025. - Mobile devices were the dominant device category, while wearable devices were the fastest-growing. - North America held about 38.4% of the market in 2025, with the United States generating about 82.5% of regional revenue. - Europe was the fastest-growing region at a projected 39.7% CAGR through 2035. - Asia-Pacific held about 22.3% of the market in 2025 and ranked second globally. - The Middle East and Africa market was valued at $0.22 billion in 2025.

Between the lines: - The report suggests SaMD is becoming easier to commercialize because regulators are creating clearer update pathways for adaptive algorithms. - Reimbursement is emerging as the bigger unlock than consumer demand, since payment codes turn software from an IT expense into a billable clinical service. - The mix of cloud training and edge inference points to a hybrid model that fits data-sovereignty requirements in the EU and Southeast Asia. - The market remains concentrated at the top, with the five largest players accounting for an estimated 32% to 38% of global revenue. - Strategic acquisitions accelerated in 2024 as larger medtech and health-IT firms bought clinical-AI startups.

What's next: - The report expects broader transatlantic regulatory convergence to shorten global go-to-market timelines from more than 36 months to under 18 months by 2035. - Procurement teams will likely keep focusing on measurable ROI, including faster diagnosis, less imaging volume and fewer avoidable readmissions. - By 2030, the report expects more semi-autonomous clinical decision loops in acute care, especially in stroke and STEMI triage. - Vendors that build stronger audit trails and explainability layers may have an advantage in high-acuity specialties. - Read the detailed insights.